

Group No.: 1642



Entitled:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maurizio Zanetti

Serial No.: 09/788,110 Filed:

02/15/2001 Examiner: Ungar, S. A Universal Vaccine and Method for Treating Cancer Employing

Telomerase Reverse Transcriptase

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA/2.

Dated: November 22, 2005

By: Cliff Cannon-Cin

Dear Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. § 1.56 and § 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed publications were cited in the International Search Report of a related application (PCT/US01/05143):

- U.S. Patent No. 5,962,320 of Robinson, "Engineered antigen presenting cells and methods for their use," (1999);
- WO 94/03205 of Kubo et al., "HLA binding peptides and their uses," (1994); and 11/29/2005 MWBLDGE1 00000001 09788110

180.00 OP 01 FC:1806

PATENT Attorney Docket No. UCSD-07017

• Vonderheide *et al.*, "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes," *Immunity*, 10:673-679 (1999).

This Information Disclosure Statement under 37 C.F.R. § 1.56 and § 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: November 22, 2005

Christine A. Lekutis Registration No. 51,934

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 415.904.6500

Chuth a. Elete

FORM PTO	449	708	IIS Department of Commerce		Attornay Dockat No.	LICSD-07017	Sarial No. 00	/700110	
(Modified) NOV		2, 8 7005 :	U.S. Department of Commerce Patent and Trademark Office STATEMENT BY APPLICANT		Attorney Docket No.: UCSD-07017 Applicant: Maurizio Zanetti		Serial No.: 09/788,110		
(37 CFR § 1.9	8 N. T.	(Use Seconal Sheet	ts If Necessary)		Filing or 371(c) Date: 02/15/2001		Group Art Unit: 1642		
			Γ	U.S. PATENT D	OCUMENTS		<u> </u>		
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	App	olicant / Patentee	Class	Subclass	Filing Date	
	1	5,962,320	10/05/99		Robinson		366	07/03/97	
				· · · · · · · · · · · · · · · · · · ·					
				-					
		<u>l</u>	FOREIGN PATENTS C	R PUBLISHED I	FOREIGN PATENT APPL	ICATIONS			
		Document	Publication Date	Cour	atry / Patent Office	Class	Subclass	Translation	
	2	Number		Cour	· · · · · · · · · · · · · · · · · · ·	Class	Subclass	Yes	No
<u></u>		WO 94/03205	02/17/94		PCT				
	<u>.</u>				 				
					e, Date, Relevant Pages, Pla				
	3	Immunity, 10:673-6	579, 1999	tic subunit is a wi	dely expressed tumor-assoc	iated antigen recogn	nized by cytotoxic	Tlympho	cytes,"
		•							
	ļ				-				
			· · · · · · · · · · · · · · · · · · ·						
-									
	<u> </u>				· · · · · · · · · · · · · · · · · · ·				***
		· ·							
							<u></u>		
									•
	<u> </u>								
	ļ								
	-								

Examiner: Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.